Want to see GANX full AI Analyst Report?
Top Page
Gain Therapeutics
(NASDAQ:GANX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-47.37% Downside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by weak financial performance (minimal revenue with persistent losses and substantial cash burn) and bearish technicals (price below key moving averages with negative MACD). A low-debt balance sheet and a positive clinical-data corporate event provide support, but not enough to offset the ongoing burn profile and downtrend.
Positive Factors
Precision-medicine platform
Gain Therapeutics has a focused discovery approach aimed at protein-misfolding diseases, using the Magnet computational platform to identify precision medicines. This gives the company a coherent scientific strategy and a basis for developing multiple candidates in CNS disorders over time.
Negative Factors
Minimal revenue and persistent losses
The company has not yet generated meaningful revenue and remains deeply unprofitable, limiting internal funding capacity and demonstrating that its business model still depends on successful clinical development. Persistent losses may continue until a product or partnership generates commercial income.
Read all positive and negative factors
Positive Factors
Negative Factors
Precision-medicine platform
Gain Therapeutics has a focused discovery approach aimed at protein-misfolding diseases, using the Magnet computational platform to identify precision medicines. This gives the company a coherent scientific strategy and a basis for developing multiple candidates in CNS disorders over time.
Read all positive factors
Gain Therapeutics (GANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.94M
Dividend YieldN/A
Average Volume (3M)482.32K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue GrowthN/A
EPS Growth23.02%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,643,620
10 Day Avg. Volume505,985
30 Day Avg. Volume482,316
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$7.20Price Target Upside278.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Gain Therapeutics Business Overview & Revenue Model
Company Description
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurologic...
Gain Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| EBITDA | -19.10M | -19.21M | -19.79M | -22.10M | -17.43M | -13.87M |
| Net Income | -20.11M | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M |
Balance Sheet | ||||||
| Total Assets | 15.42M | 22.82M | 12.12M | 18.61M | 24.10M | 38.99M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 20.84M | 10.39M | 16.79M | 20.14M | 36.88M |
| Total Debt | 609.87K | 732.07K | 653.01K | 1.03M | 1.27M | 1.61M |
| Total Liabilities | 4.13M | 4.25M | 4.78M | 6.03M | 5.22M | 4.17M |
| Stockholders Equity | 11.29M | 18.56M | 7.34M | 12.58M | 18.88M | 34.82M |
Cash Flow | ||||||
| Free Cash Flow | -18.95M | -18.47M | -18.90M | -18.88M | -14.81M | -12.46M |
| Operating Cash Flow | -18.95M | -18.47M | -18.87M | -18.87M | -14.69M | -12.37M |
| Investing Cash Flow | 0.00 | 0.00 | 4.98M | 10.22M | -14.77M | -94.21K |
| Financing Cash Flow | 25.35M | 28.45M | 13.01M | 12.64M | -78.77K | 41.77M |
Gain Therapeutics Technical Analysis
Negative
1.90
Price Trends
1.74
Negative
1.77
Negative
1.90
Negative
Market Momentum
-0.15
Positive
19.57
Positive
6.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Negative. The current price of 1.9 is above the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.74, and above the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 19.57 is Positive, neither overbought nor oversold. The STOCH value of 6.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GANX.
Gain Therapeutics Risk Analysis
Gain Therapeutics disclosed 9 risk factors in its most recent earnings report. Gain Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gain Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $104.96M | -0.96 | -78.11% | ― | ― | 9.38% | |
45 Neutral | $281.71M | -4.62 | -75.35% | ― | 220.34% | 55.73% | |
44 Neutral | $51.94M | -2.38 | -161.58% | ― | ― | 23.02% | |
42 Neutral | $24.83M | -3.39 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
GANX
Gain Therapeutics
1.29
-0.68
-34.52%
ABVC
ABVC BioPharma
1.05
-1.87
-64.14%
PMVP
PMV Pharmaceuticals
1.31
-0.28
-17.41%
PRLD
Prelude Therapeutics
3.60
2.10
140.00%
IMMX
Immix Biopharma
8.35
4.92
143.44%
Gain Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Gain Therapeutics highlights promising Parkinson’s Phase 1b data
Positive
Oct 1, 2026
On October 1, 2026, Gain Therapeutics announced new long-term open-label extension data from its Phase 1b trial of rexaceract in Parkinson’s disease, showing stabilization of Movement Disorder Society-Sponsored Revision of the Unified Parkin...
Executive/Board Changes
Gain Therapeutics Names CEO as Interim CFO
Neutral
Sep 28, 2026
On September 22, 2026, Gain Therapeutics’ Senior Vice President of Finance and principal financial and accounting officer, Gianluca Fuggetta, notified the company that he would resign effective September 30, 2026 to pursue other opportunitie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.